肝动脉灌注氟尿嘧啶、奥沙利铂联合吡柔比星治疗原发性肝癌患者的疗效  

Efficacy of hepatic arterial infusion of fluorouracil, oxaliplatin combined with pirarubicin in the treatment of patients with primary liver cancer

作　　者：王剑平 冯娟娟 王飞 裴雅玲 WANG Jianping;FENG Juanjuan;WANG Fei;PEI Yaling(Hebi People's Hospital,Hebi 458030,Henan)

机构地区：[1]鹤壁市人民医院,河南鹤壁458030

出　　处：《菏泽医学专科学校学报》2024年第4期17-20,32,共5页Journal of Heze Medical College

摘　　要：目的 探讨肝动脉灌注氟尿嘧啶、奥沙利铂联合吡柔比星对原发性肝癌患者的疗效及对血清相关因子水平变化的影响。方法 选取我院收治的原发性肝癌患者124例,随机分为两组,每组62例。对照组给予经皮肝动脉灌注化疗栓塞术(TACE)中动脉灌注氟尿嘧啶、奥沙利铂治疗,观察组在TACE中给予联合吡柔比星治疗。对比两组患者临床疗效,肿瘤标志物水平,治疗前后血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(b-FGF)、血清人类免疫缺陷病毒Ⅰ型反式激活蛋白(HTATⅠP2/TⅠP30)以及协同共刺激因子(B7-H4)水平和不良反应情况。结果 观察组总控制率高于对照组(P<0.05);治疗后两组患者肿瘤标志物水平均降低(P<0.05),且观察组低于对照组(P<0.05);治疗后两组患者VEGF、b-FGF、HTATⅠP2/TⅠP30以及B7-H4水平均降低(P<0.05),且观察组低于对照组(P<0.05);两组不良反应发生率比较,P>0.05。结论 肝动脉灌注氟尿嘧啶、奥沙利铂联合吡柔比星用于治疗原发性肝癌患者能有效降低肿瘤标志物水平,提高临床控制率,其机制可能与减少VEGF、b-FGF、HTATⅠP2/TⅠP30以及B7-H4表达水平有关。Objective To investigate the effect of hepatic arterial infusion of fluorouracil,oxaliplatin and pirarubicin on patients with primary liver cancer and its effect on serum associated factor levels.Methods 124 patients with primary liver cancer in our department were selected and randomly divided into two groups,62 cases in each group.The control group were treated with fluorouracil and oxaliplatinin during percutaneous hepatic arterial infusion chemoembolization(TACE),and the observation group were treated with pirarubicin during TACE.The clinical efficacy,tumor marker levels,the levels of vascular endothelial growth factor(VEGF),basic fibroblast growth factor(b-FGF),serum human immunodeficiency virus type I transactivator protein(HTATⅠP2/TⅠP30)and co-stimulatory factor(B7-H4)before and after treatment,and adverse reactions were compared between the two groups.Results The total control rate of the observation group was higher than that of control group(P<0.05).After treatment,tumor marker levels in both groups decreased(P<0.05),and those in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of VEGF,b-FGF,HTATⅠP2/TⅠP30 and B7-H4 in two groups decreased(P<0.05),and those in the observation group were lower than those in control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Hepatic arterial infusion of fluorouracil,oxaliplatin combined with pirarubicin in the treatment of primary liver cancer patients can effectively reduce the level of tumor markers,improve the clinical control rate,which may be related to the reduction of VEGF,b-FGF,HTATI P2/TI P30 and B7-H4 expression levels.

关 键 词：原发性肝癌 肝动脉灌注 吡柔比星 疗效 

分 类 号：R735.7[医药卫生—肿瘤]